NCT00005918已完成3 期
The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as Part of Potent Antiretroviral Combination Therapy
Bristol-Myers Squibb77 个研究点 分布在 13 个国家目标入组 730 人开始时间: 2000年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 730
- 试验地点
- 77
研究概览
简要总结
The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).
详细描述
Patients are randomized to receive blinded stavudine extended release (d4T ER) or immediate release (d4T IR) formulation. Randomization is balanced by screening HIV viral load of less than 30,000 copies/ml or at least 30,000 copies/ml and by site. Patients also receive open-label efavirenz (EFV) and lamivudine (3TC). Efficacy is evaluated over 48 weeks of the dosing period and safety is evaluated over the entire dosing period (56 weeks).
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be eligible for this study if they:
- •Are at least 18 years old. Patients living in USA, Puerto Rico, Australia, Brazil, Singapore, and Thailand can be at least 12 years old (need consent of parent or guardian if under 18).
- •Have a viral load of at least 2,000 copies/ml within 21 days of study entry.
- •Have a CD4 count of at least 100 cells/mm3 within 21 days of study entry.
- •Agree to use a barrier method of birth control (such as condoms) during the study.
- •Are available for follow-up for at least 56 weeks.
排除标准
- •Patients will not be eligible for this study if they:
- •Are pregnant or breast-feeding.
- •Have taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) for more than 30 days and within 14 days of study entry.
- •Have a new opportunistic (HIV-related) infection or condition requiring treatment.
- •Have acute (early) HIV infection.
- •Have diarrhea (at least 6 loose stools/day for at least 7 days in a row) within 30 days prior to study entry.
- •Abuse alcohol or drugs.
- •Have active hepatitis within 30 days prior to study entry.
- •Have a history of peripheral neuropathy (a condition affecting the nervous system).
- •Cannot take medications by mouth.
- •Are allergic to certain antiviral drugs.
- •Need to take certain medications that should not be taken with EFV.
- •Have certain other conditions or prior treatments that might affect the study.
研究者
研究点 (77)
Loading locations...
相似试验
已完成
2 期
Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected ChildrenHIV InfectionsNCT00000851National Institute of Allergy and Infectious Diseases (NIAID)198
已完成
3 期
Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)AIDSHIV InfectionsNCT00116298Bristol-Myers Squibb900
已完成
2 期
The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 WeeksHIV InfectionsNCT00001063National Institute of Allergy and Infectious Diseases (NIAID)200
已完成
不适用
A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.HIV InfectionsNCT00002349Bristol-Myers Squibb40
已完成
3 期
Dose Optimisation of Stavudine for the Treatment of HIV InfectionAcquired Immune Deficiency SyndromeHuman Immunodeficiency VirusNCT02670772Willem Daniel Francois Venter1,077